Last reviewed · How we verify
Ramucirumab+ paclitaxel
Ramucirumab is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, while paclitaxel is a microtubule inhibitor that blocks cell division.
Ramucirumab is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, while paclitaxel is a microtubule inhibitor that blocks cell division. Used for Metastatic gastric adenocarcinoma, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Ramucirumab+ paclitaxel |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Angiogenesis inhibitor, Microtubule inhibitor |
| Target | VEGFR2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By targeting VEGFR2, ramucirumab reduces the formation of new blood vessels that tumors need to grow. Paclitaxel works by stabilizing microtubules, preventing cell division and ultimately leading to cell death. This combination of mechanisms makes ramucirumab plus paclitaxel effective in treating certain types of cancer.
Approved indications
- Metastatic gastric adenocarcinoma, Metastatic non-small cell lung cancer
Common side effects
- Neutropenia
- Leukopenia
- Fatigue
- Anemia
- Thrombocytopenia
Key clinical trials
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (PHASE1, PHASE2)
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (PHASE3)
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Volrustomig Priming Regimens Exploratory Phase II Platform Study (PHASE2)
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (PHASE1)
- A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramucirumab+ paclitaxel CI brief — competitive landscape report
- Ramucirumab+ paclitaxel updates RSS · CI watch RSS
- AstraZeneca portfolio CI